2018 年美國糖尿病學會針對糖尿病合併高血壓之標準治療建議

郝立智, 張雅椅, 顧長生, 吳明瑞, 奚明德, 潘潔慧… - 臨床醫學 …, 2019 - airitilibrary.com
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment
for drugresistant hypertension(PATHWAY-2): a randomised, double-blind, crossover trial. …

醛固酮受体拮抗剂螺内酯治疗难治性高血压疗效和安全性的Meta 分析

张平, 邹婧, 高存州, 吴爱萍, 李蓉山 - 中国全科医学, 2022 - chinagp.net
… In terms of safety,compared with those treated with placebo,spironolactone-treated patients
Spironolactone versus placebo,bisoprolol,and doxazosin to determine the optimal treatment

[PDF][PDF] 培哚普利联合螺内酯治疗非腺瘤型原发性醛固酮增多症的临床疗效研究

王芳, 任汉强, 沈晓波, 马铭… - Progress in Modern …, 2018 - biomed.cnjournals.com
… combined with spironolactone in the treatment of patients … spironolactone orally on the basis
of conventional treatment, 3 … All patients were treated for 3 months, the clinical efficacy, and …

高血压合并低钾血症两例报道及诊断思路分析

张梓洁, 王创畅, 李荣 - 中国全科医学, 2019 - chinagp.net
… Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension[J].…
Spironolactone versus placebo,bisoprolol,and doxazosin to determine the optimal treatment

[图书][B] 高血压的社区管理与自我护理

冉凌云, 王彦 - 2021 - books.google.com
… Abstract:The prevention and treatment of hypertension is at a low level in our country.There
are many ways of community management and selfcareguidance for hypertension in the …